Biodexa Pharmaceuticals (BDRX) Operating Income (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Operating Income of -$5.4 million for Q2 2025, up 1.16% sequentially from -$5.4 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Operating Income (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Operating Income for 12 years, with the latest figure at -$5.4 million in Q2 2025.
- Quarterly Operating Income changed N/A year-over-year to -$5.4 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$20.5 million (changed N/A YoY) and the FY2025 annual result came in at -$11.4 million, up 3.46% from the prior year.
- Operating Income rose to -$5.4 million in Q2 2025 per BDRX's latest filing, from -$5.4 million in the prior quarter.
- Over five years, Operating Income peaked at -$4.4 million in Q4 2021 and troughed at -$5.4 million in Q4 2024.
- A 5-year average of -$4.9 million and a median of -$4.7 million in 2022 frame the typical range for Operating Income.
- The sharpest annual moves came in 2021 and 2022: Operating Income surged 85.67% in 2021, then declined 3.98% in 2022.
- Over 5 years, Operating Income stood at -$4.4 million in 2021, then declined by 1.65% to -$4.4 million in 2022, then declined by 19.85% to -$5.3 million in 2023, then decreased by 2.06% to -$5.4 million in 2024, then grew by 1.16% to -$5.4 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$5.4 million, -$5.4 million, and -$5.3 million for Q2 2025, Q4 2024, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -5.36 Mn |
| Dec 31, 2024 | -5.42 Mn |
| Jun 30, 2023 | -5.31 Mn |
| Dec 31, 2022 | -4.43 Mn |
| Sep 14, 2022 | -4.67 Mn |
| Dec 31, 2021 | -4.36 Mn |
| Sep 17, 2021 | -4.49 Mn |
| Dec 31, 2020 | -30.42 Mn |
| Sep 10, 2020 | -23.10 Mn |
| Dec 31, 2019 | -14.55 Mn |
| Dec 31, 2018 | -15.20 Mn |
| Dec 31, 2016 | -16.06 Mn |
| Dec 31, 2015 | -46.41 Mn |
| Dec 31, 2014 | -15.35 Mn |
| Dec 31, 2013 | -7.28 Mn |